The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial

European Journal of Clinical Pharmacology · Published 2026-05-14 · DOI 10.1007/s00228-026-04050-6

Free full text

Authors (8)

Asmaa M. Abdelkader, Hasnaa Osama, Eman S. Hassan, Bshra A. Alsfouk, Thanaa A. Elmasry, Khaled Elkhashab, Raghda R.S. Hussein, Marwa Kamal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Abdelkader, A., Osama, H., Hassan, E., et al. (2026). The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04050-6

Related articles

• Acetaminophen exposure in an aging population and neurodegenerative outcomes · European Journal of Clinical Pharmacology · 2026 · Same journal
• Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing · European Journal of Clinical Pharmacology · 2026 · Same journal
• Faster dementia progression was associated with use of potentially inappropriate medications · European Journal of Clinical Pharmacology · 2026 · Same journal
• Examining the risk of neurotoxicity in patients who receive unadjusted doses of oral beta-lactams in renal insufficiency: a retrospective cohort study · European Journal of Clinical Pharmacology · 2026 · Same journal
• Secondary data analysis of Adverse Drug Reactions reported by healthcare professionals and patients: interventions to manage ADRs of ACE inhibitors and ARBs · European Journal of Clinical Pharmacology · 2026 · Same journal
• Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools · European Journal of Clinical Pharmacology · 2026 · Same journal
• Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration · European Journal of Clinical Pharmacology · 2026 · Same journal
• Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper “prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study” · European Journal of Clinical Pharmacology · 2026 · Same journal
• Response to comment on “CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy” · European Journal of Clinical Pharmacology · 2026 · Same journal
• The role of Spanish clinical pharmacologists in economic evaluations of health technologies · European Journal of Clinical Pharmacology · 2026 · Same journal